- cafead Feb 04, 2022 at 11:32: AM
via Pfizer is taking its Valneva-partnered Lyme disease vaccine into phase 3. With midphase data supporting a three-dose series, the allies plan to kick off a phase 3 clinical trial of the regimen in the third quarter.
Valneva sold Pfizer the rights to multivalent protein subunit vaccine VLA15 for $130 million upfront in 2020. At that time, Valneva had already started two phase 2 clinical trials of the vaccine candidate. Pfizer and Valneva initiated a third midphase trial to compare two- and three-dose VLA15 regimens last year, leading to the generation of the data that has now persuaded the partners to move into phase 3.
article source
Valneva sold Pfizer the rights to multivalent protein subunit vaccine VLA15 for $130 million upfront in 2020. At that time, Valneva had already started two phase 2 clinical trials of the vaccine candidate. Pfizer and Valneva initiated a third midphase trial to compare two- and three-dose VLA15 regimens last year, leading to the generation of the data that has now persuaded the partners to move into phase 3.
article source